147 related articles for article (PubMed ID: 31479692)
1. Application of sequential serological testing strategy for detection of Hepatitis B surface antigen (HBsAg) for diagnosing HBV infection.
Tiwari AK; Pabbi S; Aggarwal G; Arora D; Bhardwaj G; Setya D; Sharma J
J Virol Methods; 2019 Dec; 274():113726. PubMed ID: 31479692
[TBL] [Abstract][Full Text] [Related]
2. One or two serological assay testing strategy for diagnosis of HBV and HCV infection? The use of predictive modelling.
Parry JV; Easterbrook P; Sands AR
BMC Infect Dis; 2017 Nov; 17(Suppl 1):705. PubMed ID: 29143611
[TBL] [Abstract][Full Text] [Related]
3. Multi-center evaluation of the hepatitis B surface antigen (HBsAg) assay and HbsAg confirmatory assay for the family of Access immunoassay systems.
Lunel-Fabiani F; Duburcq X; Levayer T; Descamps F; Maniez-Montreuil M; Pivert A; Ducancelle A; Pouzet A; Marant L; Clèment A; Duhamel D; Leirens Y; Margotteau F; Falcou-Briatte R; Heinen C; Bouniort F; Taskar S; Artus A; Woodrum D; Flecheux O
Clin Lab; 2010; 56(7-8):281-90. PubMed ID: 20857892
[TBL] [Abstract][Full Text] [Related]
4. Molecular and serological characterization of hepatitis B vaccine breakthrough infections in serial samples from two plasma donors.
Kuhns MC; McNamara AL; Holzmayer V; Cloherty GA
Virol J; 2019 Apr; 16(1):43. PubMed ID: 30943997
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the performance of four methods for detection of hepatitis B surface antigen and their application for testing 116,455 specimens.
Liu C; Chen T; Lin J; Chen H; Chen J; Lin S; Yang B; Shang H; Ou Q
J Virol Methods; 2014 Feb; 196():174-8. PubMed ID: 24239632
[TBL] [Abstract][Full Text] [Related]
6. Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System.
van Helden J; Denoyel G; Karwowska S; Reamer R; Schmalz J; Wright T; Preisel-Simmons B
Clin Lab; 2004; 50(1-2):63-73. PubMed ID: 15000222
[TBL] [Abstract][Full Text] [Related]
7. Do we need an 'in-house' neutralization assay for confirmation of hepatitis B surface antigen? Answers from a tertiary care hospital in India.
Fletcher GJ; Gnanamony M; David J; Ismail AM; Subramani T; Abraham P
J Gastroenterol Hepatol; 2010 May; 25(5):942-5. PubMed ID: 19929924
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay.
Sato S; Ohhashi W; Ihara H; Sakaya S; Kato T; Ikeda H
Transfusion; 2001 Sep; 41(9):1107-13. PubMed ID: 11552066
[TBL] [Abstract][Full Text] [Related]
9. [The significance and place of HBsAg neutralization test in the diagnosis and algorithm of hepatitis B infection].
Aytaç Ö; Toyran A; Aksoy A
Mikrobiyol Bul; 2017 Apr; 51(2):136-144. PubMed ID: 28566077
[TBL] [Abstract][Full Text] [Related]
10. Proposal of Efficient Workflows for Confirmatory Neutralization Test for Initial Hepatitis B Surface Antigen Positive Samples.
Kim SK; Huh J; Jeong TD
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625352
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
[TBL] [Abstract][Full Text] [Related]
12. The reliability of HBV core antibody in serological screening for hepatitis B virus.
Ba Alawi F; Robertson PW; LePage AK; Jayamaha J; Baleriola C; Rawlinson WD
Pathology; 2013 Aug; 45(5):501-5. PubMed ID: 23842045
[TBL] [Abstract][Full Text] [Related]
13. Performance of a new-generation chemiluminescent assay for hepatitis B surface antigen.
Chen D; Kaplan LA
Clin Chem; 2006 Aug; 52(8):1592-8. PubMed ID: 16762998
[TBL] [Abstract][Full Text] [Related]
14. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays.
Jongerius JM; Wester M; Cuypers HT; van Oostendorp WR; Lelie PN; van der Poel CL; van Leeuwen EF
Transfusion; 1998 Jan; 38(1):56-9. PubMed ID: 9482395
[TBL] [Abstract][Full Text] [Related]
15. Field performance of the Determine HBsAg point-of-care test for diagnosis of hepatitis B virus co-infection among HIV patients in Zambia.
Chisenga CC; Musukuma K; Chilengi R; Zürcher S; Munamunungu V; Siyunda A; Ojok D; Bauer S; Wandeler G; Vinikoor M;
J Clin Virol; 2018 Jan; 98():5-7. PubMed ID: 29175231
[TBL] [Abstract][Full Text] [Related]
16. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage.
Yoshikawa A; Gotanda Y; Minegishi K; Taira R; Hino S; Tadokoro K; Ohnuma H; Miyakawa K; Tachibana K; Mizoguchi H;
Transfusion; 2007 Jul; 47(7):1162-71. PubMed ID: 17581150
[TBL] [Abstract][Full Text] [Related]
17. An ultra-sensitive Abbott ARCHITECT
Lou S; Taylor R; Pearce S; Kuhns M; Leary T
J Clin Virol; 2018 Aug; 105():18-25. PubMed ID: 29843004
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).
Fiedler SA; Oberle D; Chudy M; Scheiblauer H; Henseler O; Halbauer J; Heiden M; Funk M
Vox Sang; 2019 Jul; 114(5):443-450. PubMed ID: 31012114
[TBL] [Abstract][Full Text] [Related]
19. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
Busch MP
Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
[TBL] [Abstract][Full Text] [Related]
20. Evaluating HBsAg rapid test performance for different biological samples from low and high infection rate settings & populations.
Cruz HM; Scalioni Lde P; de Paula VS; da Silva EF; do Ó KM; Milagres FA; Cruz MS; Bastos FI; Pollo-Flores P; Leal E; Motta-Castro AR; Pilotto JH; Lewis-Ximenez LL; Lampe E; Villar LM
BMC Infect Dis; 2015 Nov; 15():548. PubMed ID: 26619906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
